The 9 analysts offering 12-month price forecasts for Orchard Therapeutics PLC have a median target of 12.00, with a high estimate of 15.00 and a low estimate of 8.00. The median estimate represents a +450.46% increase from the last price of 2.18.
The current consensus among 10 polled investment analysts is to Buy stock in Orchard Therapeutics PLC. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.25
Reporting Date Nov 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.